Literature DB >> 11959455

Genetic defects in hepatobiliary transport.

Ronald Oude Elferink1, Albert K Groen.   

Abstract

Bile formation, the exocrine function of the liver, represents a process that is unique to the hepatocyte as a polarized epithelial cell. The generation of bile flow is an osmotic process and largely depends on solute secretion by primary active transporters in the apical membrane of the hepatocyte. In recent years an impressive progress has been made in the discovery of these proteins, most of which belong to the family of ABC transporters. The number of identified ABC transporter genes has been exponentially increasing and the mammalian subfamily now counts at least 52. This development has been of crucial importance for the elucidation of the mechanism of bile formation, and it is therefore not surprising that the development in this field has run in parallel with the discovery of the ABC genes. With the identification of these transporter genes, the background of a number of inherited diseases, which are caused by mutations in these solute pumps, has now been elucidated. We now know that at least six primary active transporters are involved in canalicular secretion of biliary components (MDR1, MDR3, BSEP, MRP2, BCRP and FIC1). Four of these transporter genes are associated with inherited diseases. In this minireview we will shortly describe our present understanding of bile formation and the associated inherited defects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959455     DOI: 10.1016/s0925-4439(01)00103-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  24 in total

1.  Elucidation of the biliary secretion machinery.

Authors:  Ronald Oude Elferink
Journal:  Curr Gastroenterol Rep       Date:  2003-12

Review 2.  Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein).

Authors:  Ronald P J Oude Elferink; Coen C Paulusma
Journal:  Pflugers Arch       Date:  2006-04-19       Impact factor: 3.657

3.  Hepatobiliary function assessed by 99mTc-mebrofenin cholescintigraphy in the evaluation of severity of steatosis in a rat model.

Authors:  Reeta L Veteläinen; Roelof J Bennink; Kora de Bruin; Arlène van Vliet; Thomas M van Gulik
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-10       Impact factor: 9.236

4.  Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a.

Authors:  Bin Zhang; John Groffen; Nora Heisterkamp
Journal:  Blood       Date:  2005-04-28       Impact factor: 22.113

5.  ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy.

Authors:  R Müllenbach; A Bennett; N Tetlow; N Patel; G Hamilton; F Cheng; J Chambers; R Howard; S D Taylor-Robinson; C Williamson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

6.  Treatment of hyperbilirubinemia in Eisai hyperbilirubinemic rat by transfecting human MRP2/ABCC2 gene.

Authors:  Masakazu Hirouchi; Hiroshi Suzuki; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

Review 7.  The bile salt export pump: molecular properties, function and regulation.

Authors:  Marco Arrese; Meenakshisundaram Ananthanarayanan
Journal:  Pflugers Arch       Date:  2004-07-24       Impact factor: 3.657

8.  An insertion mutation in ABCB4 is associated with gallbladder mucocele formation in dogs.

Authors:  Katrina L Mealey; Jonathan D Minch; Stephen N White; Kevin R Snekvik; John S Mattoon
Journal:  Comp Hepatol       Date:  2010-07-03

9.  Correlation analysis between four serum biomarkers of liver fibrosis and liver function in infants with cholestasis.

Authors:  Ning Tang; Yaping Zhang; Zeyu Liu; Tao Fu; Qinghong Liang; Xuemei Ai
Journal:  Biomed Rep       Date:  2016-05-18

10.  Mechanistic Modeling of the Hepatic Disposition of Estradiol-17β-Glucuronide in Sandwich-Cultured Human Hepatocytes.

Authors:  Katsuaki Ito; Noora Sjöstedt; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2019-11-19       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.